AvalehtI1DX34 • BVMF
add
Idexx Laboratories Inc Bdr
Viimane sulgemishind
516,27 R$
Aasta vahemik
476,97 R$ - 558,30 R$
Turuväärtus
33,77 mld USD
Keskmine maht
1,00
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Käive | 954,29 mln | 5,84% |
Põhitegevusega seonduv kulu | 308,97 mln | 10,01% |
Puhastulu | 216,15 mln | 11,12% |
Puhaskasumimarginaal | 22,65 | 5,01% |
Puhaskasum aktsia kohta | 2,62 | 12,93% |
EBITDA | 295,39 mln | 7,40% |
Tõhus maksumäär | 15,69% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 288,27 mln | −36,50% |
Kogu vara | 3,29 mld | 1,03% |
Kõik kohustused | 1,70 mld | −4,35% |
Kogu omakapital | 1,60 mld | — |
Emiteeritud aktsiate arv | 81,33 mln | — |
Hinna ja väärtuse suhe P/B | 26,41 | — |
Varade tasuvus | 19,69% | — |
Kapitali tasuvus | 25,17% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | 216,15 mln | 11,12% |
Põhitegevuse rahakäive | 262,02 mln | 4,87% |
Investeeringute raha | −39,84 mln | −30,91% |
Finantseerimise raha | −232,78 mln | −128,57% |
Raha ja raha ekvivalentide muutus | −20,37 mln | −116,66% |
Tasuta rahavoog | 170,52 mln | −25,07% |
Teave
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
IDEXX offers products to customers in over 175 countries around the world and employs approximately 9,200 people in full-and part-time positions. There are three main segments of the company: Companion Animal Group, Water, and Livestock, Poultry and Dairy. In addition, the company also manufactures and sells pet-side SNAP tests for a variety of animal health diagnostic uses.
In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO. Wikipedia
Tegevjuht
Asutatud
19. dets 1983
Peakontor
Veebisait
Töötajate arv
11 000
